alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### All data considered provisional and subject to revision.

      Pool Elevation                    
csv

      Storage                    
csv

      Total Release                    
csv

      Area                    
csv

      Delta Storage                    
csv

#### All data considered provisional and subject to revision.

      Pool Elevation                    
json

      Storage                    
json

      Total Release                    
json

      Area                    
json

      Delta Storage                    
json
EX-4.1





 Exhibit 4.1 

Ambrx Biopharma Inc. - Ordinary Shares 

(Incorporated under the laws of the Cayman Islands) 
  

					
	Number	  	Shares	  	                    

 Share Capital is US$60,000 divided into 600,000,000 shares consisting of 

(i) 500,000,000 Ordinary Shares of a par value of US$0.0001 each; 

(ii) 100,000,000 undesignated shares of a par value of US$0.0001 each, of such class or classes 

(however designated) as the board of directors may determine 
  

					
	THIS IS TO CERTIFY THAT	  	                                   
                                         
                    	  	
			
	is the registered holder of	  	                                   
                                         
                                	  	

 Ordinary Shares in the above-named Company subject to the Memorandum and Articles of
Association thereof. 
 EXECUTED for and on behalf of the said Company on 

by: 
  

					
	 DIRECTOR
EXHIBIT 11
<PAGE>


                          FIRST COLORADO BANCORP, INC.

                                   EXHIBIT 11
              STATEMENT REGARDING COMPUTATION OF EARNINGS PER SHARE
<TABLE>
<CAPTION>

                                                    For the three months      For the six months
                                                        Ended June 30,           Ended June 30,
                                                    1998          1997         1998           1997
                                                -----------   -----------   -----------   -----------
<S>                                             <C>           <C>           <C>           <C>        
Net Income (000's)                              $     4,200   $     4,025   $     9,006   $     8,840
                                                ===========   ===========   ===========   ===========

Weighted Average Shares Outstanding              15,707,280    15,177,188    15,684,130    15,435,250

Basic Earnings Per Share                        $      0.27   $      0.27   $      0.57   $      0.57
                                                ===========   ===========   ===========   ===========

Effect of dilutive securities:
    Stock Options                                   764,107       433,620       751,410       432,736
    Nonvested MRP/MSBP shares                        78,969        56,720        74,120        56,179
                                                -----------   -----------   -----------   -----------

Total weighted average common shares and
    equivalents outstanding for fully diluted
    computation                                  16,550,356    15,667,528    16,509,660    15,924,165
                                                ===========   ===========   ===========   ===========

Diluted earnings per share                      $      0.25   $      0.26   $      0.55   $      0.56
                                                ===========   ===========   ===========   ===========
</TABLE>


Earnings  per share of common  stock for the three and six month  periods  ended
June 30, 1998 and June 30, 1997 has been  determined  by dividing net income for
the period by the weighted average number of shares of common stock outstanding,
net of unearned ESOP shares of 918,265 and 1,072,303, respectively.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS RESTATED FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
EXTRACTED FROM THE FINANCIAL STATEMENTS OF BLOUNT INTERNATIONAL, INC. FOR THE
PERIOD ENDED JUNE 30, 1999, AS SET FORTH IN ITS FORM 10-Q FOR SUCH PERIOD
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1000000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>               DEC-31-1999
<PERIOD-END>                    JUN-30-1999
<CASH>                                             38
<SECURITIES>                                        0
<RECEIVABLES>                                     162
<ALLOWANCES>                                        4
<INVENTORY>                                       131
<CURRENT-ASSETS>                                  355
<PP&E>                                            396
<DEPRECIATION>                                    221
<TOTAL-ASSETS>                                    689
<CURRENT-LIABILITIES>                              99
<BONDS>                                           162
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<COMMON>                                            0
<OTHER-SE>                                        367
<TOTAL-LIABILITY-AND-EQUITY>                      689
<SALES>                                           368
<TOTAL-REVENUES>                                  368
<CGS>                                             263
<TOTAL-COSTS>                                     263
<OTHER-EXPENSES>                                    0
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                                  7
<INCOME-PRETAX>                                    27
<INCOME-TAX>                                       10
<INCOME-CONTINUING>                                18
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                       18
<EPS-BASIC>                                    0.24<F1>
<EPS-DILUTED>                                    0.23<F1>
<FN>
<F1> RESTATEMENT REFLECTED HEREIN IS THE RESULT OF THE PRORATION AND STOCK
ELECTION PROCEDURES RELATED TO THE AUGUST 19, 1999 MERGER AS DESCRIBED IN
NOTE 2 OF NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN
BLOUNT INTERNATIONAL, INC.'S FORM 10-Q FOR THE QUARTERLY PERIOD ENDED
SEPTEMBER 30, 1999.
</FN>


</TABLE>
CLK - CLEAR LAKE WEST LOBELatitude: 41.847Longitude: -121.209Elevation: None

CLK - Clear Lake West Lobe

Courtesy NRCS - Go to State Line Site Page...



State Line

Courtesy NRCS - Go to Strawberry Site Page...



Strawberry

Courtesy NRCS - Go to Crowder Flat Site Page...



Crowder Flat
PROVO RIVER AT PROVO, UTLatitude: 40.238Longitude: -111.699Elevation: 4519

PROVO RIVER AT PROVO, UT

Courtesy NRCS - Go to Cascade Mountain Site Page...



Cascade Mountain

Courtesy NRCS - Go to Wolf Creek Peak Site Page...



Wolf Creek Peak

Courtesy NRCS - Go to Atwater Site Page...



Atwater

Courtesy NRCS - Go to Beaver Divide Site Page...



Beaver Divide

Courtesy NRCS - Go to Brighton Site Page...



Brighton

Courtesy NRCS - Go to Daniels-Strawberry Site Page...



Daniels-Strawberry

Courtesy NRCS - Go to Thaynes Canyon Site Page...



Thaynes Canyon

Courtesy NRCS - Go to Timpanogos Divide Site Page...



Timpanogos Divide

Courtesy NRCS - Go to Trial Lake Site Page...



Trial Lake
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from
financial statements for the six months ended June 30, 2000, and is
qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                           3,347
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               161,918
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 161,918
<CURRENT-LIABILITIES>                          121,721
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,250
<OTHER-SE>                                      38,947
<TOTAL-LIABILITY-AND-EQUITY>                   161,918
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 5,059
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               3,465
<INCOME-PRETAX>                                (8,524)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (8,524)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (8,524)
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
<PAGE>


                                                                    Exhibit 23.1

                          Independent Auditors' Consent

The Board of Directors and Shareholders
Antares Pharma, Inc.:

We consent to the incorporation by reference in the registration statements
(Nos. 333-20389, 333-40483, 333-64480, 333-111177) on Form S-8, registration
statements (Nos. 333-61950, 333-96739, 333-103958) on Form S-3 and registration
statement (No. 333-109114) on Form S-2 of Antares Pharma, Inc. (formerly known
as Medi-Ject Corporation) of our reports dated February 24, 2004, except as to
note 16, which is as of March 9, 2004, with respect to the consolidated balance
sheets of Antares Pharma, Inc. and subsidiaries as of December 31, 2002 and
2003, and the related consolidated statements of operations, shareholders'
equity and comprehensive loss, and cash flows for each of the years in the
three-year period ended December 31, 2003, and the related financial statement
schedule, which reports appear in the December 31, 2003 annual report on Form
10-K of Antares Pharma, Inc.

Our report covering the December 31, 2003 consolidated financial statements
refers to the Company's adoption of provisions of Statement of Financial
Accounting Standards No. 142, Goodwill and Other Intangible Assets, on January
1, 2002.

                                              /s/ KPMG LLP



Minneapolis, Minnesota
March 29, 2004
Fourth Court of Appeals

San Antonio, Texas

August 27, 2019

No. 04-19-00567-CV

IN RE: ORDER FOR FORECLOSURE, CONCERNING 6304 RIDGEHURST, SAN 

ANTONIO, TEXAS 78250-5006

From the 285th Judicial District Court, Bexar County, Texas

Trial Court No. 2019-CI-07478

Honorable Antonia Arteaga, Judge Presiding

O R D E R

On August 22, 2019, appellant filed a notice of appeal stating its intent to appeal an order 

awarding the appellees attorney’s fees; however, the notice of appeal stated no final order was 

signed. On August 26, 2019, a deputy clerk of this court contacted the trial court regarding the 

status of the order and was informed no order will be entered.

“[T]he general rule, with a few mostly statutory exceptions, is that an appeal may be 

taken only from a final judgment.” Lehmann v. Har-Con Corp., 39 S.W.3d 191, 195 (Tex. 

2001). Because no final judgment or appealable order appears to have been entered in the 

underlying cause with regard to the payment of attorney’s fees, appellant is ORDERED to show 

cause in writing no later than two weeks from the date of this order why this appeal should not 

be dismissed for lack of jurisdiction.

_________________________________

Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 27th day of August, 2019.

___________________________________

Keith E. Hottle,

Clerk of Court
Potential LTEMP Experiments

WY 2023 

TWG 

April 11, 2023 
LTEMP ROD – Spring HFE Criteria 

2 
HFE Accounting &

Implementation Windows 

3 
USGS Preliminary Data, 2022. Do Not Cite. 

(https://www.gcmrc.gov/discharge_qw_sediment/station/GCDAMP/09382000# )

 

 

Paria River Discharge & Sand Inputs 

200,000 -500,000 more metric tons of sediment anticipated with Paria runoff. 
 

No HFE 

triggered 

• Owing to high April-June volumes, which must 

be accounted for in the sand budget model. 

• Likely would have triggered a spring HFE with a 

7.0 maf year. 

5 
Sand Load since 7/1/2022 Spring 

2023 

6 
 

 

Upper Marble Mass Balance Since 

2021 

Large sand inputs to Upper Marble Canyon occurred in Fall 2021 and Fall 2022, 

followed by little export (most of the sand is still in Upper Marble Canyon). 

7 
72-hr w/ 1 year Accounting Window 

8 
9 

Glen Canyon Dam Hourly Release Pattern April 2023 

Compare HFE Patterns 

0 

2,000 

4,000 

6,000 

8,000 

10,000 

12,000 

14,000 

16,000 

18,000 

20,000 

22,000 

24,000 

26,000 

28,000 

30,000 

32,000 

34,000 

36,000 

38,000 

40,000 

Release (cfs) 

Powerplant capacity ~25,500 

cfs 

Open bypass tubes 

April 24, 6am 

Max release ~39,500 

cfs 

At full capacity 

Apr 24, 9am 

Begin 

downramp 

39,500 cfs 

Apr 27, 9am 

HFE ends 

Apr 27, 10pm 

HFE begins 

Apr 24, 2am 

 

4/01 - Sat 

4/02 - Sun 

4/03 - Mon 

4/04 - Tue 

4/05 - Wed 

4/06 - Thu 

4/07 - Fri 

4/08 - Sat 

4/09 - Sun 

4/10 - Mon 

4/11 - Tue 

4/12 - Wed 

4/13 - Thu 

4/14 - Fri 

4/15 - Sat 

4/16 - Sun 

4/17 - Mon 

4/18 - Tue 

4/19 - Wed 

4/20 - Thu 

4/21 - Fri 

4/22 - Sat 

4/23 - Sun 

4/24 - Mon 

4/25 - Tue 

4/26 - Wed 

4/27 - Thu 

4/28 - Fri 

4/29 - Sat 

4/30 - Sun 

5/01 - Mon 

72-Hour HFE Actual Hourly Releases Lees Ferry Flow 
 

 

Proposed Spring Experiment 

• 8 unit + full bypass available 

• 72 hr duration 

• Very close to an LTEMP trigger 

• Based on a 1-yr accounting window since most sediment 

is still in Marble Canyon from 2022. 

• Used a Supplemental Information Report for this 

Experiment because of exceptional conditions that exist. 

• 39,500 cfs magnitude 

• 270 kaf moved 

• April 24-27, 2023 

• Within-month experiment 

10 
Resources 

• Smallmouth bass & other non-native fishes 

• 1) Entrainment 

• 2) Warmer summer releases 

• 3) Pushing fish downstream 

• Hydropower - $1.4M 

• Hydrology 

• Water quality 

11 
Rest of WY23 

• LTEMP menu also includes for consideration: 

• Bug Flows 

• TMFs 

• Fall accounting window starts July 1, 2023. 

• High flows through remainder of WY 2023. 

12 
Send comments/feedback to: 

Clarence Fullard 

cfullard@usbr.gov 
14 
= HFE 

15
SAN ANTONIO RIVER AT ORTIZLatitude: 36.998Longitude: -106.031Elevation: 8781

SAN ANTONIO RIVER AT ORTIZ

Courtesy NRCS - Go to San Antonio Sink Site Page...



San Antonio Sink

Courtesy NRCS - Go to Bateman Site Page...



Bateman

Courtesy NRCS - Go to Hopewell Site Page...



Hopewell
#### Joseph Dothage *v.*The United States.

*On the Proofs.*

*This suit is brought under the st Abandoned or captured property act,” (\2 Scat. L.f*820,) *to recover the net proceeds of two bales of cotton captured in the city of Charleston. There is no direct proof of loyalty.*

In the absence of proof of disloyalty merely, there cannot be a recovery under the *“Abandoned or captured property act,”*(Stat. L., 820 ) Direct and positive proof of loyalty is required to justify a recovery.

*Mr. D. S.*Cooley, for tbe claimant.

*Mr. E. S.*Sale, special counsel for the Treasury, for the defendants.

Milligan, J.,

delivered the opinion of the court :•

This is an action brought under the act of the 12th of March, 1863, to recover the proceeds of the sales of two bales of cotton alleged to have been captured in the city of Charleston by the United States forces, and shipped to New York and there sold, and the proceeds paid into the treasury.

The action cannot be maintained. There is literally no proof of the claimant’s loyalty in the records, without which, under the plain provisions of the statute, he has no standing in this court.

One witness states that he lived in the same house with the plaintiff in 1864, and heard him often talk about the war, but he never said much 'for the one side or for the other. Another witness swears, “ he talked with him during the war,” and heard him say, *“*the sooner the war was over the better,” but he said little or nothing of his own position.

There is no other endorser, if indeed this can be called testimony, which even tends to establish the loyalty of the claimant; and under the statute and settled rulings of this court the action in such a case cannot be maintained.

The petition is therefore dismissed.
#### All data considered provisional and subject to revision.

      Flow                    
csv

      Ave Water Level                    
csv

#### All data considered provisional and subject to revision.

      Flow                    
json

      Ave Water Level                    
json
#### UNITED STATES of America, Plaintiff-Appellee, v. Tyrone D. GOODIN, Defendant-Appellant.

No. 06-30093

Summary Calendar.

United States Court of Appeals, Fifth Circuit.

May 17, 2007.

Cristina Walker, Assistant U.S. Attorney, James G. Cowles, Jr., Assistant U.S. Attorney, U.S. Attorney’s Office Western District of Louisiana, Shreveport, LA, for Plaintiff-Appellee.

W. Jarred Franklin, Bossier City, LA, for Defendant-Appellant.

Before REAVLEY, GARZA and BENAVIDES, Circuit Judges.

PER CURIAM: *

Tyrone D. Goodin appeals his guilty-plea conviction and 18-month sentence for possession of an unregistered firearm. Goo-din contends that the district court erred in denying his motions to suppress. Goo-din has waived this issue by entering an unconditional guilty plea. *See United States v. Wise,*179 F.3d 184, 186 (5th Cir.1999); *United States v. Bell,*966 F.2d 914, 916-17 (5th Cir.1992).

*491Goodin avers that his sentence was unreasonable and that the district court erred in declining to depart downward. This court does not have jurisdiction to review the district court’s denial of Goo-din’s motion for a downward departure. *See United States v. Hernandez,*457 F.3d 416, 424 (5th Cir.2006).

However, we do have jurisdiction to review “whether the district court’s imposition of a guideline sentence instead of a non-guideline sentence was reasonable.” *See United States v. Nikonova,*480 F.3d 371, 375 (5th Cir.2007). The district court properly calculated the applicable guideline sentencing range and considered the sentencing factors set forth in 18 U.S.C. § 3553(a). *See United States v. Mares,*402 F.3d 511, 518-20 (5th Cir.2005). Therefore, Goodin has not shown that the sentence imposed by the district court was unreasonable. *See id.*

AFFIRMED.

*

 Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               Amendment No. 1 to
                                  FORM 10-QSB/A

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

               For the quarterly period ended: September 30, 2003

                                       OR

[_]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

                        Commission file number: 000-23339

                            US GLOBAL NANOSPACE, INC.
             (Exact name of registrant as specified in its charter)

                 Delaware                                     13-3720542
     (State or other jurisdiction of                       (I.R.S. Employer
      Incorporation or organization)                       Identification No.)

                      2533 North Carson Street, Suite 5107
                            Carson City, Nevada 89706
                    (Address of principal executive offices)

                                  775-841-3246
               (Registrant's telephone number including area code)

                            US Global Aerospace, Inc.
              (Former name, former address and former fiscal year,
                         if changed since last report)

<PAGE>

                                EXPLANATORY NOTE

      The purpose of this amendment is to file complete copies of exhibit number
10.1,  Patent and Technology  License  Agreement dated July 24, 2003 between the
Registrant and TIAX LLC, and exhibit number 10.2,  Amendment No. 1 to Patent and
Technology  License  Agreement  dated October 3, 2003 between the Registrant and
TIAX LLC, which were previously filed in incomplete form.

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly caused this  Amendment  No. 1 to  quarterly  report on Form
10-QSB to be signed on its behalf by the undersigned thereunto duly authorized.


                                US GLOBAL NANOSPACE, INC.


                                By:  /s/ John Robinson
                                     ------------------------------------------
Date:  February 9, 2005              John Robinson, Chief Executive Officer


                                By:  /s/ Julie Seaman
                                     ------------------------------------------
Date:  February 9, 2005              Julie Seaman, Chief Financial Officer